The presence of non‐hepatic malignancy and its implication in pursuing liver transplantation

2021 ◽  
Author(s):  
Maneerat Chayanupatkul ◽  
Maya Gambarin‐Gelwan ◽  
Thomas D Schiano
2007 ◽  
Vol 39 (10) ◽  
pp. 3512-3514 ◽  
Author(s):  
S. Fayek ◽  
D. Moore ◽  
K.H. Bortecen ◽  
H. Yeh ◽  
J.F. Markmann ◽  
...  

1999 ◽  
Vol 67 (10) ◽  
pp. 1369-1372 ◽  
Author(s):  
Jarmo Laine ◽  
Hannu Jalanko ◽  
Ulla M. Saarinen-Pihkala ◽  
Krister Hockerstedt ◽  
Mauri Leijala ◽  
...  

1990 ◽  
Vol 77 (9) ◽  
pp. 983-987 ◽  
Author(s):  
T. Ismail ◽  
L. Angrisani ◽  
B. K. Gunson ◽  
S. G. Hübscher ◽  
J. A. C. Buckets ◽  
...  

2006 ◽  
Vol 4 (8) ◽  
pp. 762-767 ◽  
Author(s):  
Jean F. Botha ◽  
Alan N. Langnas

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and the most common primary hepatic malignancy. It arises on a background of hepatic cirrhosis in approximately 95% of the cases in the United States. A wide variety of treatment modalities have been applied in the treatment of HCC. Liver transplantation has emerged as the preferred treatment for patients with small HCC. Transplantation for patients whose tumors do not exceed the Milan criteria yields results equivalent to those of transplantation for non-HCC indications. Controversy now exists regarding the use of living donors, expansion of selection criteria, and role of adjuvant therapy.


1987 ◽  
Vol 1 (1) ◽  
pp. 171-182
Author(s):  
Rex J Polson ◽  
John G. O'Grady ◽  
Roger Williams

2021 ◽  
Vol 21 (8) ◽  
pp. 2905-2907
Author(s):  
Jennifer L. Carpenter ◽  
Nada A. Yazigi ◽  
Thomas M. Fishbein ◽  
Juan F. Guerra

Surgery ◽  
2006 ◽  
Vol 139 (4) ◽  
pp. 535-541
Author(s):  
Amit D. Tevar ◽  
Paul Succop ◽  
Chris R. Schneider ◽  
Thav Thambi-Pillai ◽  
Mark J. Thomas ◽  
...  

2020 ◽  
Vol 35 (11) ◽  
Author(s):  
Gil-Chun Park ◽  
Shin Hwang ◽  
Chul-Soo Ahn ◽  
Ki-Hun Kim ◽  
Deok-Bog Moon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document